Amgen Inc. (AMGN) Shares Bought by FTB Advisors Inc.

FTB Advisors Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 809.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,710 shares of the medical research company’s stock after buying an additional 16,652 shares during the period. FTB Advisors Inc.’s holdings in Amgen were worth $3,062,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in AMGN. Thomas J. Herzfeld Advisors Inc. purchased a new position in Amgen during the fourth quarter valued at about $102,000. Alpha Omega Wealth Management LLC increased its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Focused Wealth Management Inc increased its position in Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock valued at $127,000 after buying an additional 620 shares in the last quarter. Finally, Signature Estate & Investment Advisors LLC increased its position in Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares in the last quarter. Institutional investors and hedge funds own 78.80% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) opened at 177.40 on Tuesday. The firm’s 50-day moving average price is $162.22 and its 200-day moving average price is $162.64. The company has a market cap of $130.46 billion, a PE ratio of 16.85 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The firm had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the business earned $2.90 earnings per share. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. Equities research analysts forecast that Amgen Inc. will post $12.47 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://transcriptdaily.com/2017/07/18/amgen-inc-amgn-shares-bought-by-ftb-advisors-inc.html.

Several research analysts have issued reports on AMGN shares. Jefferies Group LLC downgraded Amgen from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $194.00 to $180.00 in a report on Wednesday, April 5th. Credit Suisse Group reaffirmed a “hold” rating and set a $178.00 price objective on shares of Amgen in a report on Tuesday, April 4th. Vetr raised Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price objective on the stock in a report on Monday, March 27th. Cowen and Company reaffirmed an “outperform” rating and set a $209.00 price objective on shares of Amgen in a report on Wednesday, April 19th. Finally, Morgan Stanley upped their price objective on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company. Amgen presently has an average rating of “Buy” and an average target price of $185.17.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply